https://orcid.org/0000-0002-7616-3872
References
- Békés M, Langley DR, Crews CM. 2022. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 21(3):181–200. doi:10.1038/s41573-021-00371-6.
- Cantrill C, Chaturvedi P, Rynn C, Petrig Schaffland J, Walter I, Wittwer MB. 2020. Fundamental aspects of DMPK optimization of targeted protein degraders. Drug Discov Today. 25(6):969–982. doi:10.1016/j.drudis.2020.03.012.
- Fang Y, Wang S, Han S, Zhao Y, Yu C, Liu H, Li N. 2023. Targeted protein degrader development for cancer: advances, challenges, and opportunities. Trends Pharmacol Sci. 44(5):303–317. doi:10.1016/j.tips.2023.03.003.
- Garcia Jimenez D, Vallaro M, Rossi Sebastiano M, Apprato G, D'Agostini G, Rossetti P, Ermondi G, Caron G. 2023. Chamelogk: a chromatographic chameleonicity quantifier to design orally bioavailable beyond-rule-of-5 drugs. J Med Chem. 66(15):10681–10693. doi:10.1021/acs.jmedchem.3c00823.
- Guzzetti S, Morentin Gutierrez P. 2023. An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions. J Pharmacokinet Pharmacodyn. 50(5):327–349. doi:10.1007/s10928-023-09857-9.
- Haid RTU, Reichel A. 2023. A mechanistic pharmacodynamic modeling framework for the assessment and optimization of proteolysis targeting chimeras (PROTACs). Pharmaceutics. 15(1):195. eng. doi:10.3390/pharmaceutics15010195.
- Lai AC, Crews CM. 2017. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 16(2):101–114. doi:10.1038/nrd.2016.211.
- Pike A, Williamson B, Harlfinger S, Martin S, McGinnity DF. 2020. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discov Today. 25(10):1793–1800. doi:10.1016/j.drudis.2020.07.013.
- Teng M, Gray NS. 2023. The rise of degrader drugs. Cell Chem Biol. 30(8):864–878. doi:10.1016/j.chembiol.2023.06.020.
- Volak LP, Duevel HM, Humphreys S, Nettleton D, Phipps C, Pike A, Rynn C, Scott-Stevens P, Zhang D, Zientek M. 2023. Industry perspective on the pharmacokinetic and absorption, distribution, metabolism, and excretion characterization of heterobifunctional protein degraders. Drug Metab Dispos. 51(7):792–803. doi:10.1124/dmd.122.001154.